Stephen McNeeney

Stephen is a patent attorney with nearly 30 years’ experience in the pharmaceutical and life sciences sector. He advises clients ranging from start-ups to multinationals, drawing on a background in chemistry and deep expertise in patent strategy and global portfolio management.

Stephen has worked in the patent profession for over 30 years, helping clients across the pharmaceutical and life sciences sector realise the value of their IP. His clients range from major pharmaceutical companies to start-ups, SMEs and university spin-outs, many of which are based outside the UK, particularly in Sweden.

Steve manages clients’ patent portfolios on a global scale, devising patent strategies and coordinating ongoing prosecution. This enables clients to generate and then make effective use of their IP through legal defence, out-licensing, due diligence, supporting inward investment and planning exit strategies. His expertise has led to involvement in assisting SME clients in defending their rights in US courts, including proceedings under the Hatch-Waxman Act, where he instructs and assists US counsel with litigation strategy, argumentation and witness preparation.

Steve also played a pivotal role in securing and defending two patents at the European Patent Office (EPO) for AstraZeneca’s Nexium® (esomeprazole), successfully upholding those patents against opposition from 13 generic pharmaceutical companies.

‍